Doubling down on oncology, Sanofi buys into a new checkpoint inhibitor with a $125M down payment

Nicole DeFeudis

Editor

On its latest shopping trip through the immuno-oncology department, Sanofi picked up the rights to a checkpoint inhibitor from Biond Biologics’ pipeline, paying over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Doubling down on oncology, Sanofi buys into a new checkpoint inhibitor with a $125M down payment

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Doubling down on oncology, Sanofi buys into a new checkpoint inhibitor with a $125M down payment

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya